Trial Outcomes & Findings for S1204, Viral Screening in Newly Diagnosed Cancer Patients (NCT NCT01946516)
NCT ID: NCT01946516
Last Updated: 2023-07-03
Results Overview
An estimate of the prevalence of human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection among newly diagnosed cancer participants presenting to SWOG-affiliated community and academic oncology clinics.
Recruitment status
COMPLETED
Target enrollment
3051 participants
Primary outcome timeframe
Up to 21 days after registration
Results posted on
2023-07-03
Participant Flow
3092 participants were screened for the trial; 41 were deemed ineligible and 3051 eligible participants were registered to the trial.
Participant milestones
| Measure |
HBV, HCV, or HIV Prevalence
Participants received testing for at least one of the following, HBV, HCV, or HIV.
|
|---|---|
|
Overall Study
STARTED
|
3051
|
|
Overall Study
Evaluated for HBV Status
|
3050
|
|
Overall Study
Evaluated for HCV Status
|
2990
|
|
Overall Study
Evaluated for HIV Status
|
3045
|
|
Overall Study
COMPLETED
|
3051
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
S1204, Viral Screening in Newly Diagnosed Cancer Patients
Baseline characteristics by cohort
| Measure |
Participants With Newly Diagnosed Cancer
n=3051 Participants
Participants with newly diagnosed cancer that underwent viral testing for at least one of the following: HBV, HCV, and HIV.
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=93 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
1967 Participants
n=93 Participants
|
|
Age, Categorical
>=65 years
|
1084 Participants
n=93 Participants
|
|
Age, Continuous
|
60.6 years
n=93 Participants
|
|
Sex: Female, Male
Female
|
1842 Participants
n=93 Participants
|
|
Sex: Female, Male
Male
|
1209 Participants
n=93 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
558 Participants
n=93 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
2478 Participants
n=93 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
15 Participants
n=93 Participants
|
|
Race/Ethnicity, Customized
Race · White
|
2281 Participants
n=93 Participants
|
|
Race/Ethnicity, Customized
Race · Black
|
553 Participants
n=93 Participants
|
|
Race/Ethnicity, Customized
Race · Asian
|
102 Participants
n=93 Participants
|
|
Race/Ethnicity, Customized
Race · Other
|
115 Participants
n=93 Participants
|
|
Cancer Type
Blood or marrow
|
369 Participants
n=93 Participants
|
|
Cancer Type
Breast
|
1058 Participants
n=93 Participants
|
|
Cancer Type
Gastrointestinal tract, colorectal
|
362 Participants
n=93 Participants
|
|
Cancer Type
Gastrointestinal, liver
|
62 Participants
n=93 Participants
|
|
Cancer Type
Gastrointestinal, other
|
235 Participants
n=93 Participants
|
|
Cancer Type
Head and neck
|
112 Participants
n=93 Participants
|
|
Cancer Type
Lung
|
356 Participants
n=93 Participants
|
|
Cancer Type
Prostate
|
100 Participants
n=93 Participants
|
|
Cancer Type
Other
|
392 Participants
n=93 Participants
|
|
Cancer Type
Missing
|
5 Participants
n=93 Participants
|
|
Region
West and Midwest United States
|
1096 Participants
n=93 Participants
|
|
Region
South and Northeast United States
|
1955 Participants
n=93 Participants
|
PRIMARY outcome
Timeframe: Up to 21 days after registrationPopulation: The analysis population includes the 3051 participants eligible to receive at least one viral test (for HBV, HCV, or HIV). 3050 participants were evaluable for HBV analysis (1 participants had no HBV test results available), 2990 participants were evaluable for HCV analysis (5 participants had no HCV test results available and 56 participants incomplete test results), and 3045 participants were evaluable for HIV analysis (6 participants had no HIV test results available).
An estimate of the prevalence of human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection among newly diagnosed cancer participants presenting to SWOG-affiliated community and academic oncology clinics.
Outcome measures
| Measure |
Evaluated for Chronic HBV
n=3050 Participants
Participants who were evaluated for chronic HBV.
|
Evaluated for Previous HBV
n=3050 Participants
Participants who were evaluated for previous HBV analysis.
|
Evaluated for HCV
n=2990 Participants
Participants who were evaluated for HCV..
|
Evaluated for HIV
n=3045 Participants
Participants who were evaluated for HIV analysis.
|
Participants With Any Type Of Viral Infection
Participants diagnosed with any type of viral infection.
|
|---|---|---|---|---|---|
|
Number of Participants With Positive Viral Infection
Positive Viral Test in All Participants
|
19 Participants
|
197 Participants
|
71 Participants
|
34 Participants
|
—
|
|
Number of Participants With Positive Viral Infection
Positive Viral Test in Newly Diagnosed Participants
|
8 Participants
|
172 Participants
|
22 Participants
|
2 Participants
|
—
|
|
Number of Participants With Positive Viral Infection
Positive Viral Test in Participants with Blood/Marrow Cancer
|
2 Participants
|
16 Participants
|
9 Participants
|
7 Participants
|
—
|
|
Number of Participants With Positive Viral Infection
Positive Viral Test in Participants with Prostate Cancer
|
0 Participants
|
12 Participants
|
3 Participants
|
1 Participants
|
—
|
|
Number of Participants With Positive Viral Infection
Positive Viral Test in Previously Diagnosed Participants
|
11 Participants
|
25 Participants
|
49 Participants
|
32 Participants
|
—
|
|
Number of Participants With Positive Viral Infection
Positive Viral Test in Participants with Breast Cancer
|
4 Participants
|
66 Participants
|
9 Participants
|
2 Participants
|
—
|
|
Number of Participants With Positive Viral Infection
Positive Viral Test in Participants with Colorectal Cancer
|
2 Participants
|
18 Participants
|
7 Participants
|
5 Participants
|
—
|
|
Number of Participants With Positive Viral Infection
Positive Viral Test in Participants with Liver Cancer
|
4 Participants
|
5 Participants
|
9 Participants
|
0 Participants
|
—
|
|
Number of Participants With Positive Viral Infection
Positive Viral Test in Participants with GI, Other Tract Cancer
|
3 Participants
|
22 Participants
|
3 Participants
|
5 Participants
|
—
|
|
Number of Participants With Positive Viral Infection
Positive Viral Test in Participants with Head and Neck Cancer
|
1 Participants
|
9 Participants
|
5 Participants
|
1 Participants
|
—
|
|
Number of Participants With Positive Viral Infection
Positive Viral Test in Participants with Lung Cancer
|
2 Participants
|
31 Participants
|
17 Participants
|
4 Participants
|
—
|
|
Number of Participants With Positive Viral Infection
Positive Viral Test in Participants with Other Cancer
|
1 Participants
|
18 Participants
|
9 Participants
|
9 Participants
|
—
|
SECONDARY outcome
Timeframe: Up to 21 days after registrationPopulation: The analysis population includes the 2940 of the 3050 participants who were evaluable for HBV analysis and completed the risk factor survey.
The presence or absence of specific risk factors among participants evaluated for previous HBV is evaluated.
Outcome measures
| Measure |
Evaluated for Chronic HBV
n=190 Participants
Participants who were evaluated for chronic HBV.
|
Evaluated for Previous HBV
n=2750 Participants
Participants who were evaluated for previous HBV analysis.
|
Evaluated for HCV
Participants who were evaluated for HCV..
|
Evaluated for HIV
Participants who were evaluated for HIV analysis.
|
Participants With Any Type Of Viral Infection
Participants diagnosed with any type of viral infection.
|
|---|---|---|---|---|---|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Needle-stick exposure · Risk Factor Present
|
12 Participants
|
136 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Needle-stick exposure · Risk Factor Absent
|
178 Participants
|
2614 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Household contact with hepatitis-positive person · Risk Factor Present
|
15 Participants
|
171 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Unprotected sex with MSM, multiple, or anonymous partners · Risk Factor Present
|
14 Participants
|
103 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Unprotected sex with MSM, multiple, or anonymous partners · Risk Factor Absent
|
176 Participants
|
2647 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Household contact with hepatitis-positive person · Risk Factor Absent
|
175 Participants
|
2579 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
High-risk occupation · Risk Factor Present
|
11 Participants
|
190 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
High-risk occupation · Risk Factor Absent
|
179 Participants
|
2560 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Completed HBV vaccine (3 or more doses) · Risk Factor Present
|
8 Participants
|
236 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Completed HBV vaccine (3 or more doses) · Risk Factor Absent
|
182 Participants
|
2514 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Sexual contact with HIV-positive person · Risk Factor Present
|
14 Participants
|
25 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Sexual contact with HIV-positive person · Risk Factor Absent
|
176 Participants
|
2725 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Self-reported infection with HCV or HIV · Risk Factor Present
|
41 Participants
|
135 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Self-reported infection with HCV or HIV · Risk Factor Absent
|
149 Participants
|
2615 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Born in high HBV prevalence region · Risk Factor Present
|
63 Participants
|
243 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Born in high HBV prevalence region · Risk Factor Absent
|
127 Participants
|
2507 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Injected drug use · Risk Factor Present
|
21 Participants
|
86 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Injected drug use · Risk Factor Absent
|
169 Participants
|
2664 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Unprotected sex with high-risk person · Risk Factor Present
|
21 Participants
|
109 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Unprotected sex with high-risk person · Risk Factor Absent
|
169 Participants
|
2641 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Sexual contact with hepatitis-positive person · Risk Factor Present
|
10 Participants
|
56 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Sexual contact with hepatitis-positive person · Risk Factor Absent
|
180 Participants
|
2694 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Diagnosis or treatment for STD · Risk Factor Present
|
32 Participants
|
276 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Diagnosis or treatment for STD · Risk Factor Absent
|
158 Participants
|
2474 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Blood transfusion between 1978-1985 · Risk Factor Present
|
13 Participants
|
110 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Previous HBV
Blood transfusion between 1978-1985 · Risk Factor Absent
|
177 Participants
|
2640 Participants
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 21 days after registrationPopulation: The analysis population includes the 2940 of the 3050 participants who were evaluable for HBV analysis and completed the risk factor survey.
The presence or absence of specific risk factors among participants evaluated for chronic HBV is evaluated.
Outcome measures
| Measure |
Evaluated for Chronic HBV
n=18 Participants
Participants who were evaluated for chronic HBV.
|
Evaluated for Previous HBV
n=2922 Participants
Participants who were evaluated for previous HBV analysis.
|
Evaluated for HCV
Participants who were evaluated for HCV..
|
Evaluated for HIV
Participants who were evaluated for HIV analysis.
|
Participants With Any Type Of Viral Infection
Participants diagnosed with any type of viral infection.
|
|---|---|---|---|---|---|
|
Presence of Important Risk Factors in Participants Tested for Chronic HBV
Needle-stick exposure · Risk Factor Absent
|
15 Participants
|
2777 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Chronic HBV
Diagnosis or treatment for STD · Risk Factor Absent
|
14 Participants
|
2618 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Chronic HBV
Self-reported infection with HCV or HIV · Risk Factor Present
|
2 Participants
|
174 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Chronic HBV
Born in high HBV prevalence region · Risk Factor Present
|
8 Participants
|
298 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Chronic HBV
Born in high HBV prevalence region · Risk Factor Absent
|
10 Participants
|
2624 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Chronic HBV
Needle-stick exposure · Risk Factor Present
|
3 Participants
|
145 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Chronic HBV
Unprotected sex with MSM, multiple, or anonymous partners · Risk Factor Present
|
2 Participants
|
115 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Chronic HBV
Unprotected sex with MSM, multiple, or anonymous partners · Risk Factor Absent
|
16 Participants
|
2807 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Chronic HBV
Unprotected sex with high-risk person · Risk Factor Present
|
2 Participants
|
128 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Chronic HBV
Unprotected sex with high-risk person · Risk Factor Absent
|
16 Participants
|
2794 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Chronic HBV
Sexual contact with hepatitis-positive person · Risk Factor Present
|
1 Participants
|
65 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Chronic HBV
Sexual contact with hepatitis-positive person · Risk Factor Absent
|
17 Participants
|
2857 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Chronic HBV
Diagnosis or treatment for STD · Risk Factor Present
|
4 Participants
|
304 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Chronic HBV
Self-reported infection with HCV or HIV · Risk Factor Absent
|
16 Participants
|
2748 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Chronic HBV
Household contact with hepatitis-positive person · Risk Factor Present
|
1 Participants
|
185 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for Chronic HBV
Household contact with hepatitis-positive person · Risk Factor Absent
|
17 Participants
|
2737 Participants
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 21 days after registrationPopulation: The analysis population includes the 2882 of the 2990 participants who were evaluable for HCV analysis completed the risk factor survey.
The presence or absence of specific risk factors among participants evaluated for HCV is evaluated.
Outcome measures
| Measure |
Evaluated for Chronic HBV
n=69 Participants
Participants who were evaluated for chronic HBV.
|
Evaluated for Previous HBV
n=2813 Participants
Participants who were evaluated for previous HBV analysis.
|
Evaluated for HCV
Participants who were evaluated for HCV..
|
Evaluated for HIV
Participants who were evaluated for HIV analysis.
|
Participants With Any Type Of Viral Infection
Participants diagnosed with any type of viral infection.
|
|---|---|---|---|---|---|
|
Presence of Important Risk Factors in Participants Tested for HCV
Injected drug use · Risk Factor Absent
|
48 Participants
|
2746 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HCV
Tested because born between 1945-1965 · Risk Factor Absent
|
58 Participants
|
2687 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HCV
Self-reported infection with HIV · Risk Factor Present
|
4 Participants
|
48 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HCV
Injected drug use · Risk Factor Present
|
21 Participants
|
67 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HCV
Tested because of blood exposure, injected drug use, or transfusion before 1992 · Risk Factor Present
|
9 Participants
|
45 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HCV
Tested because of blood exposure, injected drug use, or transfusion before 1992 · Risk Factor Absent
|
60 Participants
|
2768 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HCV
Tested because of symptoms · Risk Factor Present
|
7 Participants
|
46 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HCV
Tested because of symptoms · Risk Factor Absent
|
62 Participants
|
2767 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HCV
Blood transfusion between 1978-1985 · Risk Factor Present
|
11 Participants
|
104 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HCV
Blood transfusion between 1978-1985 · Risk Factor Absent
|
58 Participants
|
2709 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HCV
Tested because born between 1945-1965 · Risk Factor Present
|
11 Participants
|
126 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HCV
Self-reported infection with HIV · Risk Factor Absent
|
65 Participants
|
2765 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HCV
Snorted cocaine · Risk Factor Present
|
15 Participants
|
254 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HCV
Snorted cocaine · Risk Factor Absent
|
54 Participants
|
2559 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HCV
Needle-stick exposure · Risk Factor Present
|
7 Participants
|
134 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HCV
Needle-stick exposure · Risk Factor Absent
|
62 Participants
|
2679 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HCV
High-risk occupation · Risk Factor Present
|
3 Participants
|
195 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HCV
High-risk occupation · Risk Factor Absent
|
66 Participants
|
2618 Participants
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 21 days after registrationPopulation: The analysis population includes the 2934 of the 3045 participants were evaluable for HIV analysis and completed the risk factor survey.
The presence or absence of specific risk factors among participants evaluated for HIV is evaluated.
Outcome measures
| Measure |
Evaluated for Chronic HBV
n=34 Participants
Participants who were evaluated for chronic HBV.
|
Evaluated for Previous HBV
n=2900 Participants
Participants who were evaluated for previous HBV analysis.
|
Evaluated for HCV
Participants who were evaluated for HCV..
|
Evaluated for HIV
Participants who were evaluated for HIV analysis.
|
Participants With Any Type Of Viral Infection
Participants diagnosed with any type of viral infection.
|
|---|---|---|---|---|---|
|
Presence of Important Risk Factors in Participants Tested for HIV
Sexual contact with HIV-positive person · Risk Factor Present
|
16 Participants
|
23 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HIV
Sexual contact with HIV-positive person · Risk Factor Absent
|
18 Participants
|
2877 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HIV
Unprotected sex with MSM, multiple, or anonymous partners · Risk Factor Present
|
16 Participants
|
101 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HIV
Unprotected sex with MSM, multiple, or anonymous partners · Risk Factor Absent
|
18 Participants
|
2799 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HIV
Diagnosis or treatment for STD · Risk Factor Present
|
20 Participants
|
288 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HIV
Diagnosis or treatment for STD · Risk Factor Absent
|
14 Participants
|
2612 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HIV
Unprotected sex with high-risk person · Risk Factor Present
|
12 Participants
|
118 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HIV
Unprotected sex with high-risk person · Risk Factor Absent
|
22 Participants
|
2782 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HIV
Self-reported infection with HBV · Risk Factor Present
|
4 Participants
|
51 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HIV
Self-reported infection with HBV · Risk Factor Absent
|
30 Participants
|
2849 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HIV
Diagnosis or treatment for tuberculosis · Risk Factor Present
|
5 Participants
|
92 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HIV
Diagnosis or treatment for tuberculosis · Risk Factor Absent
|
29 Participants
|
2808 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HIV
Injected drug use · Risk Factor Present
|
3 Participants
|
104 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HIV
Injected drug use · Risk Factor Absent
|
31 Participants
|
2796 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HIV
Needle-stick exposure · Risk Factor Present
|
1 Participants
|
147 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HIV
Needle-stick exposure · Risk Factor Absent
|
33 Participants
|
2753 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HIV
High-risk occupation · Risk Factor Present
|
1 Participants
|
199 Participants
|
—
|
—
|
—
|
|
Presence of Important Risk Factors in Participants Tested for HIV
High-risk occupation · Risk Factor Absent
|
33 Participants
|
2701 Participants
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: 60 days after registrationPopulation: The analysis population includes the 224 participants who were viral positive for at least one viral test (for HBV, HCV, or HIV) and had treatment outcome data available. Of the 292 patients were who were viral positive for at least one viral test, 11 patients did not have data submitted and 57 patients did not have data available.
Among participants with HIV, HBV, or HCV, the timing and type of treatments received, both for the viral infections and the cancers that were evaluated.
Outcome measures
| Measure |
Evaluated for Chronic HBV
n=152 Participants
Participants who were evaluated for chronic HBV.
|
Evaluated for Previous HBV
n=15 Participants
Participants who were evaluated for previous HBV analysis.
|
Evaluated for HCV
n=49 Participants
Participants who were evaluated for HCV..
|
Evaluated for HIV
n=30 Participants
Participants who were evaluated for HIV analysis.
|
Participants With Any Type Of Viral Infection
n=224 Participants
Participants diagnosed with any type of viral infection.
|
|---|---|---|---|---|---|
|
Type of Treatment for Cancer and Virus in Participants With Positive Viral Test
Received Antiviral or Antiretroviral Drugs
|
11.8 percentage of participants
|
73.3 percentage of participants
|
8.2 percentage of participants
|
66.7 percentage of participants
|
19.6 percentage of participants
|
|
Type of Treatment for Cancer and Virus in Participants With Positive Viral Test
Change in Cancer Treatment
|
59.2 percentage of participants
|
53.3 percentage of participants
|
55.1 percentage of participants
|
50 percentage of participants
|
58.5 percentage of participants
|
|
Type of Treatment for Cancer and Virus in Participants With Positive Viral Test
Change in Cancer Treatment due to Viral Positive Status
|
7.9 percentage of participants
|
13.3 percentage of participants
|
6.1 percentage of participants
|
16.7 percentage of participants
|
8 percentage of participants
|
|
Type of Treatment for Cancer and Virus in Participants With Positive Viral Test
Change in Cancer Treatment due to Viral Positive Status and Added Antiviral or Antiretroviral Drugs
|
5.3 percentage of participants
|
13.3 percentage of participants
|
2 percentage of participants
|
13.3 percentage of participants
|
6.3 percentage of participants
|
SECONDARY outcome
Timeframe: 5 years after registrationEstimate type and rate of cancer-treatment related adverse events among persons with HIV, HBV, and/or HCV infection.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 3 years after registrationEstimate the cost-effectiveness of screening for HIV, HBV, and HCV.
Outcome measures
Outcome data not reported
Adverse Events
HBV, HCV, or HIV Prevalence
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Cancer Care Delivery Committee Statistician
SWOG Statistics and Data Management Center
Phone: 2066674623
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: LTE60